Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING NA

Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)

NCT07308847 · View on ClinicalTrials.gov ↗

Study Summary

The study is a prospective, single-arm, pre-market clinical study and will enroll up to 300 subjects at up to 26 sites in the United States (US) for analysis of primary objectives. No single site may contribute more than 15% of the enrollments.

Conditions Studied

Interventions

  • DEVICE Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System

Study Locations (9)

Massachusetts

  • Massachusetts General Hospital — Boston
  • Southcoast Health System — Fall River

New York

  • Icahn School of Medicine at Mount Sinai — New York
  • Northwell Health Lenox Hill Hospital — New York

Arkansas

  • Arrhythmia Research Group — Jonesboro

Illinois

  • Northwestern University — Chicago

North Carolina

  • Atrium Health Wake Forest Baptist Medical Center — Winston-Salem

Ohio

  • The Ohio State University Wexner Medical Center — Columbus

Texas

  • Texas Cardiac Arrhythmia Research Foundation — Austin

Trial Details

FieldValue
Enrollment Target 300 participants
Start Date 2026-01-15
Est. Completion 2027-11-22
Phase NA

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT07308847

The ClinicalTrials.gov registry entry for NCT07308847 describes a study currently listed as recruiting. It is categorized as NA, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medtronic Cardiac Ablation Solutions, which has 12 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Paroxysmal AF appearing as the primary indexed condition, and to 1 intervention — of which Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT07308847 reports 9 study locations spanning 7 distinct geographic areas — top geographies include Massachusetts, New York, Arkansas. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT07308847 about?

NCT07308847 is a clinical study titled "Horizon 360 Protocol for the Treatment of Paroxysmal Atrial Fibrillation With the Sphere-360™ Catheter and Affera™ Mapping and Ablation System (Horizon 360)". The study is a prospective, single-arm, pre-market clinical study and will enroll up to 300 subjects at up to 26 sites in the United States (US) for analysis of primary objectives. No single site may contribute more than 15% of the enrollments.

What is the current status of trial NCT07308847?

This trial is currently recruiting. It is a NA study. The enrollment target is 300 participants. The study started on 2026-01-15. Estimated completion is 2027-11-22.

What conditions does trial NCT07308847 study?

This clinical trial studies the following conditions: Paroxysmal AF. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT07308847?

The interventions under investigation include: Sphere-360 Pulsed Field Ablation Catheter with the Affera Mapping and Ablation System (DEVICE). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT07308847?

This trial is sponsored by Medtronic Cardiac Ablation Solutions, which has 12 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT07308847 being conducted?

This trial has 9 study locations across Arkansas, Illinois, Massachusetts, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial